

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/133167 A1

(43) International Publication Date
01 July 2021 (01.07.2021)

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/10 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/NL2020/050813

(22) International Filing Date:

22 December 2020 (22.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2024576 24 December 2019 (24.12.2019) NL

(71) Applicant: MERUS N.V. [NL/NL]; Yalelaan 62, 3584 CM Utrecht (NL).

(72) Inventor: THROSBY, Mark; c/o Yalelaan 62, 3584 CM Utrecht (NL).

(74) Agent: WITMANS, H.A.; V.O., P.O. Box 87930, 2508 DH Den Haag (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TGF-BETA-RII BINDING PROTEINS

(57) Abstract: The present invention relates to an antibody or antibody fragment thereof that specifically binds to the extracellular domain of human TGF- β RII. The present invention further relates to a vector comprising a polynucleotide encoding the antibody or antibody fragment of the invention, an isolated cell producing the antibody or antibody fragment of the invention, and a pharmaceutical composition comprising the antibody or antibody fragment of the invention. The antibody or antibody fragment of the invention can be used to treat cancer.



WO 2021/133167 A1